Biological pacemaker

Last updated

A biological pacemaker is one or more types of cellular components that, when "implanted or injected into certain regions of the heart," produce specific electrical stimuli that mimic that of the body's natural pacemaker cells. [1] Biological pacemakers are indicated for issues such as heart block, slow heart rate, and asynchronous heart ventricle contractions. [2] [3]

The biological pacemaker is intended as an alternative to the artificial cardiac pacemaker that has been in human use since the late 1950s. Despite their success, several limitations and problems with artificial pacemakers have emerged during the past decades such as electrode fracture or damage to insulation, infection, re-operations for battery exchange, and venous thrombosis. The need for an alternative is most obvious in children, including premature newborn babies, where size mismatch and the fact that pacemaker leads do not grow with children are a problem. [1] A more biological approach has been taken in order to mitigate many of these issues. However, the implanted biological pacemaker cells still typically need to be supplemented with an artificial pacemaker while the cells form the necessary electrical connections with cardiac tissue. [1]

History

The first successful experiment with biological pacemakers was carried out by Arjang Ruhparwar 's group at Hannover Medical School in Germany using transplanted fetal heart muscle cells. The process was first introduced at the scientific sessions of the American Heart Association in Anaheim in 2001, and the results were published in 2002. [4] A few months later, Eduardo Marban's group from Johns Hopkins University published the first successful gene-therapeutic approach towards the generation of pacemaking activity in otherwise non-pacemaking adult cardiomyocytes using a guinea pig model. [5] The investigators postulated latent pacemaker capability in normal heart muscle cells. This potential ability is suppressed by the inward-rectifier potassium current Ik1 encoded by the gene Kir2 which is not expressed in pacemaker cells. By specific inhibition of Ik1 below a certain level, spontaneous activity of cardiomyocytes was observed with resemblance to the action potential pattern of genuine pacemaker cells.

Meanwhile, other genes and cells have been discovered, including heart muscle cells derived from embryonic stem cells, "HCN" genes which encode the wild type pacemaker current I(f). Michael Rosen's group demonstrated that transplantation of HCN2-transfected human mesenchymal stem cells (hMSCs) leads to expression of functional HCN2 channels in vitro and in vivo, mimicking overexpression of HCN2 genes in cardiac myocytes. [6] In 2010, Ruhparwar's group again demonstrated a type of biological pacemaker, this time showing that by injection of the "Adenylate Cyclase" gene into the heart muscle a biological cardiac pacemaker can be created. [7]

In 2014, a gene called TBX18 has been non-invasively applied to speed up heart rates caused by heart block. [2] More recent studies in 2015, has been experimented optogenetic approach in the rats heart, where a light sensitive transgene (Channelrhodopsin-2) injected to several sites of rat's ventricular, which, furthermore, can simultaneously stimulate the injection sites by a blue light irradiation. [3]

Related Research Articles

<span class="mw-page-title-main">Bradycardia</span> Heart rate below the normal range

Bradycardia is a medical term used to describe a resting heart rate under 60 beats per minute (BPM). While bradycardia can result from a variety of pathologic processes, it is commonly a physiologic response to cardiovascular conditioning, or due to asymptomatic type 1 atrioventricular block. Resting heart rates less than 50 BPM are often normal during sleep in young and healthy adults, and in athletes. In large population studies of adults without underlying heart disease, resting heart rates of 45-50 BPM appear to be the lower limits of normal, dependent on age and sex. Bradycardia is most likely to be discovered in the elderly, as both age and underlying cardiac disease progression contribute to its development.

<span class="mw-page-title-main">Artificial cardiac pacemaker</span> Medical device

An artificial cardiac pacemaker is a medical device, nowadays always implanted, that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart, the upper atria or lower ventricles. Each pulse causes the targeted chamber(s) to contract and pump blood, thus regulating the function of the electrical conduction system of the heart.

<span class="mw-page-title-main">Cardiac pacemaker</span> Network of cells that facilitate rhythmic heart contraction

The contraction of cardiac muscle in all animals is initiated by electrical impulses known as action potentials that in the heart are known as cardiac action potentials. The rate at which these impulses fire controls the rate of cardiac contraction, that is, the heart rate. The cells that create these rhythmic impulses, setting the pace for blood pumping, are called pacemaker cells, and they directly control the heart rate. They make up the cardiac pacemaker, that is, the natural pacemaker of the heart. In most humans, the highest concentration of pacemaker cells is in the sinoatrial (SA) node, the natural and primary pacemaker, and the resultant rhythm is a sinus rhythm.

<span class="mw-page-title-main">Purkinje fibers</span> Fibers in the wall of the heart

The Purkinje fibers are located in the inner ventricular walls of the heart, just beneath the endocardium in a space called the subendocardium. The Purkinje fibers are specialized conducting fibers composed of electrically excitable cells. They are larger than cardiomyocytes with fewer myofibrils and many mitochondria. They conduct cardiac action potentials more quickly and efficiently than any of the other cells in the heart's electrical conduction system. Purkinje fibers allow the heart's conduction system to create synchronized contractions of its ventricles, and are essential for maintaining a consistent heart rhythm.

<span class="mw-page-title-main">Atrial natriuretic peptide</span> Cardiac hormone which increases renal sodium excretion

Atrial natriuretic peptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac atria that in humans is encoded by the NPPA gene. Natriuretic peptides are a family of hormone/paracrine factors that are structurally related. The main function of ANP is causing a reduction in expanded extracellular fluid (ECF) volume by increasing renal sodium excretion. ANP is synthesized and secreted by cardiac muscle cells in the walls of the atria in the heart. These cells contain volume receptors which respond to increased stretching of the atrial wall due to increased atrial blood volume.

<span class="mw-page-title-main">Cardiac conduction system</span> Aspect of heart function

The cardiac conduction system transmits the signals generated by the sinoatrial node – the heart's pacemaker, to cause the heart muscle to contract, and pump blood through the body's circulatory system. The pacemaking signal travels through the right atrium to the atrioventricular node, along the bundle of His, and through the bundle branches to Purkinje fibers in the walls of the ventricles. The Purkinje fibers transmit the signals more rapidly to stimulate contraction of the ventricles.

<span class="mw-page-title-main">Cell therapy</span> Therapy in which cellular material is injected into a patient

Cell therapy is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues.

<span class="mw-page-title-main">T-tubule</span> Extensions in cell membrane of muscle fibres

T-tubules are extensions of the cell membrane that penetrate into the center of skeletal and cardiac muscle cells. With membranes that contain large concentrations of ion channels, transporters, and pumps, T-tubules permit rapid transmission of the action potential into the cell, and also play an important role in regulating cellular calcium concentration.

Cardiomyoplasty is a surgical procedure in which healthy muscle from another part of the body is wrapped around the heart to provide support for the failing heart. Most often the latissimus dorsi muscle is used for this purpose. A special pacemaker is implanted to make the skeletal muscle contract. If cardiomyoplasty is successful and increased cardiac output is achieved, it usually acts as a bridging therapy, giving time for damaged myocardium to be treated in other ways, such as remodeling by cellular therapies.

<span class="mw-page-title-main">Ryanodine receptor 2</span> Transport protein and coding gene in humans

Ryanodine receptor 2 (RYR2) is one of a class of ryanodine receptors and a protein found primarily in cardiac muscle. In humans, it is encoded by the RYR2 gene. In the process of cardiac calcium-induced calcium release, RYR2 is the major mediator for sarcoplasmic release of stored calcium ions.

<span class="mw-page-title-main">GATA4</span> Protein-coding gene in the species Homo sapiens

Transcription factor GATA-4 is a protein that in humans is encoded by the GATA4 gene.

<span class="mw-page-title-main">HCN2</span> Protein-coding gene in the species Homo sapiens

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated ion channel 2 is a protein that in humans is encoded by the HCN2 gene.

<span class="mw-page-title-main">MYL4</span> Protein-coding gene in the species Homo sapiens

Atrial Light Chain-1 (ALC-1), also known as Essential Light Chain, Atrial is a protein that in humans is encoded by the MYL4 gene. ALC-1 is expressed in fetal cardiac ventricular and fetal skeletal muscle, as well as fetal and adult cardiac atrial tissue. ALC-1 expression is reactivated in human ventricular myocardium in various cardiac muscle diseases, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy and congenital heart diseases.

<span class="mw-page-title-main">HCN4</span> Protein-coding gene in the species Homo sapiens

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 is a protein that in humans is encoded by the HCN4 gene.

<span class="mw-page-title-main">BRL-32872</span> Chemical compound

BRL-32872 is an experimental drug candidate that provides a novel approach to the treatment of cardiac arrhythmia. Being a derivative of verapamil, it possesses the ability to inhibit Ca+2 membrane channels. Specific modifications in hydrogen bonding activity, nitrogen lone pair availability, and molecular flexibility allow BRL-32872 to inhibit K+ channels as well. As such, BRL-32872 is classified as both a class III (K+ blocking) and class IV (Ca+2 blocking) antiarrhythmic agent.

Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure with symptoms despite optimal medical therapy who can benefit from an improvement in cardiac output. The short- and long-term use of this therapy enhances the strength of ventricular contraction and therefore the heart's pumping capacity by modulating (adjusting) the myocardial contractility. This is provided by a pacemaker-like device that applies non-excitatory electrical signals adjusted to and synchronized with the electrical action in the cardiac cycle.

Tbx18 transduction is a method of turning on genes in heart muscle cells as a treatment for certain cardiac arrhythmias. Currently this therapy is in the very early stages of experimentation, having only been applied to rodents. Before this treatment can be used in humans, successful tests on larger animals need to be completed followed by human clinical trials. This treatment is one of the many forms of gene therapy that are currently being researched for use in different diseases.

Human engineered cardiac tissues (hECTs) are derived by experimental manipulation of pluripotent stem cells, such as human embryonic stem cells (hESCs) and, more recently, human induced pluripotent stem cells (hiPSCs) to differentiate into human cardiomyocytes. Interest in these bioengineered cardiac tissues has risen due to their potential use in cardiovascular research and clinical therapies. These tissues provide a unique in vitro model to study cardiac physiology with a species-specific advantage over cultured animal cells in experimental studies. hECTs also have therapeutic potential for in vivo regeneration of heart muscle. hECTs provide a valuable resource to reproduce the normal development of human heart tissue, understand the development of human cardiovascular disease (CVD), and may lead to engineered tissue-based therapies for CVD patients.

Regeneration in humans is the regrowth of lost tissues or organs in response to injury. This is in contrast to wound healing, or partial regeneration, which involves closing up the injury site with some gradation of scar tissue. Some tissues such as skin, the vas deferens, and large organs including the liver can regrow quite readily, while others have been thought to have little or no capacity for regeneration following an injury.

References

  1. 1 2 3 Kenknight, B.; Girouard, S.D. (2013). "Chapter 3: Genetics - Patent Issued for Method for Controlling Pacemaker Therapy". In Acton, Q.A. (ed.). Arrhythmia: New Insights for the Healthcare Professional. Atlanta, GA: ScholarlyEditions. pp. 27–60. ISBN   9781481650717 . Retrieved 18 February 2016.
  2. 1 2 Ellis, Marie (17 July 2014). "Scientists create 'biological pacemakers' by transplanting gene into hearts". Medical News Today. MediLexicon International Ltd. Retrieved 18 February 2016.
  3. 1 2 Hattori, K. (22 June 2015). "Blue light sets the beat in biological pacemaker". Science Daily. Retrieved 18 February 2016.
  4. ↑ Ruhparwar, A.; Tebbenjohanns, J.; Niehaus, M.; et al. (2002). "Transplanted fetal cardiomyocytes as cardiac pacemaker". European Journal of Cardio-Thoracic Surgery. 21 (5): 853–857. doi: 10.1016/S1010-7940(02)00066-0 . PMID   12062274.
  5. ↑ Miake, J.; Marbán, E.; Nuss, H.B. (2002). "Biological pacemaker created by gene transfer". Nature. 419 (6903): 132–133. doi:10.1038/419132b. PMID   12226654. S2CID   4318994.
  6. ↑ Plotnikov, A.N.; Sosunov, E.A.; Qu, J.; et al. (2004). "Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates". Circulation. 109 (4): 506–512. CiteSeerX   10.1.1.510.4284 . doi: 10.1161/01.CIR.0000114527.10764.CC . PMID   14734518.
  7. ↑ Ruhparwar, A.; Kallenbach, K.; Klein, G.; et al. (2010). "Adenylate-cyclase VI transforms ventricular cardiomyocytes into biological pacemaker cells". Tissue Engineering Part A. 16 (6): 1867–1872. doi:10.1089/ten.tea.2009.0537. PMID   20067385.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.